Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Fri, 03/22/2024 – 12:34
Read more about Novartis Fabhalta® (iptacopan) receives…
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Novartis shareholders approve all resolutions proposed by the Board of Directors a…
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Les actionnaires de Novartis approuvent toutes le…
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen…
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
arcticnovartis
Mon, 03/04/2024 – 07:19
Read more about Novartis presents new data on safety an…
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
arcticnovartis
Mon, 02/05/2024 – 22:48
Read more about Novartis to strengthen oncology pipeline with agreement…
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
arcticnovartis
Wed, 01/31/2024 – 07:02
Read…
Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
arcticnovartis
Wed, 01/31/2024 – 07:02
Read more abou…
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
arcticnovartis
Wed, 01/31/2024 – 07:02
Read more abo…
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis
Fri, 01/19/2024 – 16:04
Read more about Novartis Lu…